1 이영완, "한미가 개발한 유전자 가위, 중국만 신났다"
2 전예진, "인간배아 연구 규제 완화해야 하나"
3 전방욱, "인간 배아 유전체 편집에 관한 윤리적 쟁점" 한국생명윤리학회 16 (16): 17-30, 2015
4 전방욱, "유전자 편집에 근거한 유전자치료 연구의 윤리" 한국의료윤리학회 19 (19): 47-59, 2016
5 한국과학기술한림원, "생명윤리법 제46조, 지금 기술 수준에 맞게 개정해야"
6 "배아줄기·유전자치료 연구 범위 확대..생명윤리 규제개선"
7 강기헌, "“질병 종류 관계없이 유전자 치료 허용” 신용현, 생명윤리법 개정안 대표 발의"
8 Ravven W., "The stem-cell revolution is coming - Slowly"
9 Sinsheimer, R. L., "The prospect for designed genetic change" 57 (57): 134-142, 1969
10 Doudna, J. A., "The new frontier of genome engineering with CRISPR-Cas9" 346 (346): 1258096-, 2014
1 이영완, "한미가 개발한 유전자 가위, 중국만 신났다"
2 전예진, "인간배아 연구 규제 완화해야 하나"
3 전방욱, "인간 배아 유전체 편집에 관한 윤리적 쟁점" 한국생명윤리학회 16 (16): 17-30, 2015
4 전방욱, "유전자 편집에 근거한 유전자치료 연구의 윤리" 한국의료윤리학회 19 (19): 47-59, 2016
5 한국과학기술한림원, "생명윤리법 제46조, 지금 기술 수준에 맞게 개정해야"
6 "배아줄기·유전자치료 연구 범위 확대..생명윤리 규제개선"
7 강기헌, "“질병 종류 관계없이 유전자 치료 허용” 신용현, 생명윤리법 개정안 대표 발의"
8 Ravven W., "The stem-cell revolution is coming - Slowly"
9 Sinsheimer, R. L., "The prospect for designed genetic change" 57 (57): 134-142, 1969
10 Doudna, J. A., "The new frontier of genome engineering with CRISPR-Cas9" 346 (346): 1258096-, 2014
11 Parkman, R., "The application of bone marrow transplantation to the treatment of genetic diseases" 232 (232): 1373-1378, 1986
12 Cui, X., "Targeted integration in rat and mouse embryos with zinc-finger nucleases" 29 (29): 64-67, 2011
13 Blaese, R. M., "T Lymphocyte-Directed Gene Therapy for ADA-SCID: Initial Trial Results After 4 Years" 475-480, 1995
14 Friedmann, T., "Progress toward human gene therapy" 244 (244): 1275-1281, 1989
15 Morsy, M. A., "Progress toward human gene therapy" 270 (270): 2338-2345, 1993
16 Miller, A. D., "Progress toward human gene therapy" 76 (76): 271-278, 1990
17 Thomas, C. E., "Progress and problems with the use of viral vectors for gene therapy" 4 (4): 346-358, 2003
18 Komor, A. C., "Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage" 533 (533): 420-424, 2016
19 Badran, A. H., "Programmable base editing of A• T to G• C in genomic DNA without DNA cleavage" 551 (551): 464-, 2017
20 "OMIM Gene map statistics"
21 Geurts, A. M., "Knockout rats via embryo microinjection of zinc-finger nucleases" 325 (325): 433-, 2009
22 Kang, X., "Introducing precise genetic modifications into human 3PN embryos by CRISPR/Cas-mediated genome editing" 33 (33): 581-588, 2016
23 Egli, D., "Inter-homologue repair in fertilized human eggs?"
24 Howe, S. J., "Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients" 118 (118): 3143-, 2008
25 Walters, L., "Human gene therapy: ethics and public policy" 2 (2): 115-122, 1991
26 Zhou, C., "Highly efficient base editing in human tripronuclear zygotes" 8 (8): 772-775, 2017
27 Ishii, T., "Germ line genome editing in clinics: the approaches, objectives and global society" 16 (16): 46-56, 2017
28 Fogarty, N. M., "Genome editing reveals a role for OCT4 in human embryogenesis" 550 (550): 67-73, 2017
29 Weber, G. F., "Gene therapy–Why can it fail?" 80 (80): 613-616, 2013
30 Naldini, L., "Gene therapy returns to centre stage" 526 (526): 351-360, 2015
31 Kohn, D. B., "Gene therapy fulfilling its promise" 360 (360): 518-, 2009
32 Friedmann, T., "Gene therapy for human genetic disease?" 175 (175): 949-955, 1972
33 Marshall, E., "Gene therapy death prompts review of adenovirus vector" 286 (286): 2244-2245, 1999
34 Ma, G., "Gene medicine for cancer treatment: commercially available medicine and accumulated clinical data in China" 2 : 115-, 2008
35 Tebas, P., "Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV" 370 (370): 901-910, 2014
36 Lanphier, E., "Don't edit the human germ line" 519 (519): 410-, 2015
37 Liang, P., "Correction of β-thalassemia mutant by base editor in human embryos" 1-12, 2017
38 Ma, H., "Correction of a pathogenic gene mutation in human embryos" 548 (548): 413-419, 2017
39 Council of Europe, "Convention for the protection of Human Rights and Dignity of the Human Being with regard to the Application of Biology and Medicine: Convention on Human Rights and Biomedicine"
40 Roemer, K., "Concepts and strategies for human gene therapy" 208 : 211-225, 1992
41 Tang, L., "CRISPR/Cas9-mediated gene editing in human zygotes using Cas9 protein" 292 (292): 525-533, 2017
42 Liang, P., "CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes" 6 (6): 363-372, 2015
43 Wang, H., "CRISPR/Cas9 in genome editing and beyond" 85 : 227-264, 2016
44 Lundberg, A. S., "CRISPR-Cas gene editing to cure serious diseases: treat the patient, not the germ line" 15 (15): 38-40, 2015
45 Cyranoski, D., "CRISPR gene-editing tested in a person for the first time" 539 (539): 479-, 2016
46 Lander, E. S., "Brave new genome" 373 (373): 5-8, 2015
47 Lek, M., "Analysis of protein-coding genetic variation in 60,706 humans" 536 (536): 285-291, 2016
48 Cho, S. W., "Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases" 24 (24): 132-141, 2014
49 Savić, N., "Advances in therapeutic CRISPR/Cas9 genome editing" 168 : 15-21, 2016
50 Baltimore, D., "A prudent path forward for genomic engineering and germline gene modification" 348 (348): 36-38, 2015
51 최준호, "3조 시장 유전자 치료 한국은 손발 묶였다"